Semnur Pharmaceuticals, Inc. 8-K

What Happened
Semnur Pharmaceuticals (SMNR) filed an 8‑K on March 17, 2026 disclosing that Jaisim Shah retired and resigned as Chief Executive Officer, President and director effective March 13, 2026. The board reduced its size from six to five directors. The board appointed Henry Ji, Ph.D., who had served as Executive Chairperson since September 2025, as Chief Executive Officer and President effective March 13, 2026. The company also appointed Stephen Ma as Chief Operating Officer effective March 17, 2026. Mr. Shah’s departure was reported as not resulting from any disagreement with the company.

Key Details

• Separation agreement with Jaisim Shah: six months of continued base salary (base salary reference $1,250,000 per year) and a 90‑day extension to exercise any vested stock options; prior employment agreement dated September 22, 2025 was terminated. Agreement includes a general release.
• Board change: size decreased from six directors to five immediately after Mr. Shah’s resignation (effective March 13, 2026).
• Leadership appointments: Henry Ji (internal executive and long‑time director) named CEO/President effective March 13, 2026; Stephen Ma (previously CFO/SVP/Secretary) named COO effective March 17, 2026. Company stated no change to compensation for Ji or Ma in connection with their new roles.
• Related-party and transaction context: Scilex (the company’s controlling stockholder) remains a significant holder following the September 22, 2025 business combination; a transition services agreement with Scilex caps services at $2.0 million per year for up to three years. On closing of the business combination, the Sponsor received $1,143,959.16 in cash and the company issued a Sponsor Note for $806,366.78 (payable in monthly installments, with acceleration provisions).

Why It Matters
This is a material leadership change: a founder/CEO departure and immediate appointment of an experienced internal executive (Dr. Ji) and promotion of the CFO to COO. The company recorded a modest severance obligation (six months’ pay) and equity-exercise extension, but said the new CEO and COO salaries were unchanged. For investors, key takeaways are management continuity through internal promotions, the continued influence of Scilex as controlling stockholder, and the existence of related‑party arrangements (transition services and the Sponsor Note) that could affect near‑term cash flows and operations.